- Published on
Ophthalmology – Conjunctival Lymphoma
Conjunctival lymphoma is part of a spectrum of lymphoid tumors ranging from benign reactive hyperplasia to malignant lymphoma. It represents a form of extranodal lymphoma, meaning it arises outside lymph nodes, and accounts for a small proportion of all lymphomas. Within the eye, lymphoma can involve multiple structures including the conjunctiva, orbit, eyelid, uvea, retina, and vitreous. Importantly, conjunctival lymphoma may be the first manifestation of a systemic, potentially life-threatening lymphoma, making early recognition critical.
Clinically, it most often affects middle-aged to older adults and is rare in children. Patients may present with a painless, pink (“salmon-patch”) conjunctival mass, which is a key hallmark. Some individuals notice irritation, tearing, or a visible lesion, while others are completely asymptomatic. The tumor commonly arises in the fornix or midbulbar conjunctiva and can occasionally be multifocal or bilateral. Although many cases are initially localized, a significant proportion of patients may later develop systemic lymphoma, sometimes even decades after the ocular diagnosis.
The underlying pathophysiology is not fully understood, but many cases are classified as MALT (mucosa-associated lymphoid tissue) lymphoma. Chronic immune stimulation is believed to play a role, possibly related to infections such as Helicobacter pylori or Chlamydia psittaci, or autoimmune diseases like Sjögren’s syndrome or Hashimoto thyroiditis. Genetic abnormalities, including chromosomal translocations, have also been identified in some cases.
Diagnosis begins with clinical suspicion based on appearance, but definitive diagnosis requires biopsy. Histopathology helps distinguish between reactive hyperplasia, atypical lymphoid proliferation, and true malignant lymphoma. Additional evaluation includes CBC to rule out leukemia, as well as imaging—preferably orbital MRI—to assess for local extension. Because of the risk of systemic involvement, patients require long-term systemic surveillance, often with periodic imaging and medical evaluation.
Management depends on the extent and behavior of the tumor. Small, localized lesions may be treated with complete surgical excision combined with cryotherapy. If the lesion is diffuse or involves critical structures, an incisional biopsy followed by therapy is preferred. Treatment options include radiotherapy, which is highly effective due to the radiosensitive nature of lymphoma, as well as chemotherapy and immunotherapy (e.g., rituximab). Some clinicians also use antibiotics targeting suspected infectious triggers.
Long-term follow-up is essential, as recurrence or systemic progression can occur even many years later. Patients are typically monitored at least twice yearly with ocular exams and periodic systemic evaluation. Prognosis is generally favorable for localized disease, but the risk of systemic lymphoma varies—higher in bilateral cases than unilateral ones. Potential complications include ocular motility problems, ptosis, diplopia, or vision loss, particularly after treatment.
Conjunctival lymphoma is part of a spectrum of lymphoid tumors ranging from benign reactive hyperplasia to malignant lymphoma. It represents a form of extranodal lymphoma, meaning it arises outside lymph nodes, and accounts for a small proportion of all lymphomas. Within the eye, lymphoma can involve multiple structures including the conjunctiva, orbit, eyelid, uvea, retina, and vitreous. Importantly, conjunctival lymphoma may be the first manifestation of a systemic, potentially life-threatening lymphoma, making early recognition critical.
Clinically, it most often affects middle-aged to older adults and is rare in children. Patients may present with a painless, pink (“salmon-patch”) conjunctival mass, which is a key hallmark. Some individuals notice irritation, tearing, or a visible lesion, while others are completely asymptomatic. The tumor commonly arises in the fornix or midbulbar conjunctiva and can occasionally be multifocal or bilateral. Although many cases are initially localized, a significant proportion of patients may later develop systemic lymphoma, sometimes even decades after the ocular diagnosis.
The underlying pathophysiology is not fully understood, but many cases are classified as MALT (mucosa-associated lymphoid tissue) lymphoma. Chronic immune stimulation is believed to play a role, possibly related to infections such as Helicobacter pylori or Chlamydia psittaci, or autoimmune diseases like Sjögren’s syndrome or Hashimoto thyroiditis. Genetic abnormalities, including chromosomal translocations, have also been identified in some cases.
Diagnosis begins with clinical suspicion based on appearance, but definitive diagnosis requires biopsy. Histopathology helps distinguish between reactive hyperplasia, atypical lymphoid proliferation, and true malignant lymphoma. Additional evaluation includes CBC to rule out leukemia, as well as imaging—preferably orbital MRI—to assess for local extension. Because of the risk of systemic involvement, patients require long-term systemic surveillance, often with periodic imaging and medical evaluation.
Management depends on the extent and behavior of the tumor. Small, localized lesions may be treated with complete surgical excision combined with cryotherapy. If the lesion is diffuse or involves critical structures, an incisional biopsy followed by therapy is preferred. Treatment options include radiotherapy, which is highly effective due to the radiosensitive nature of lymphoma, as well as chemotherapy and immunotherapy (e.g., rituximab). Some clinicians also use antibiotics targeting suspected infectious triggers.
Long-term follow-up is essential, as recurrence or systemic progression can occur even many years later. Patients are typically monitored at least twice yearly with ocular exams and periodic systemic evaluation. Prognosis is generally favorable for localized disease, but the risk of systemic lymphoma varies—higher in bilateral cases than unilateral ones. Potential complications include ocular motility problems, ptosis, diplopia, or vision loss, particularly after treatment.
- Published on
Ophthalmology – Congenital Hypopigmented Retinal Lesions
Congenital hypopigmented retinal lesions are a diverse group of conditions characterized by reduced or absent pigmentation of the retinal pigment epithelium (RPE) or choroid present at birth. These lesions are not a single disease entity but rather include a wide spectrum of pathologies such as tumors, congenital infections, retinal dystrophies, and developmental abnormalities. Clinically, they may appear as white or pale areas in the fundus and can vary in size, location, and associated findings.
A critical point in evaluation is that any white retinal lesion in infancy must prompt urgent consideration of Retinoblastoma, a life-threatening malignancy. Other important causes include infectious etiologies such as Toxoplasmosis, Cytomegalovirus infection, and Varicella, which typically produce chorioretinal scars. Developmental anomalies like Coloboma and inherited retinal dystrophies such as Leber congenital amaurosis are also included in the differential diagnosis.
The underlying pathophysiology depends on the cause. In some cases, there is a primary defect in melanin production within the RPE, while in others, such as infections, there is destruction of the RPE. Developmental conditions like coloboma result from failure of closure of the embryonic fissure, leading to absence of normal retinal and choroidal structures. Neoplastic processes, such as retinoblastoma or astrocytic hamartoma, involve abnormal cellular proliferation.
Patients may present with leukocoria, decreased vision, strabismus, or may be asymptomatic with incidental findings on examination. Associated systemic features are common, particularly in congenital infections and genetic syndromes. Diagnosis relies on a thorough ophthalmic examination supported by imaging such as ocular ultrasound (especially useful for detecting calcification in retinoblastoma), MRI or CT for intracranial or orbital involvement, and laboratory testing including TORCH screening and genetic analysis when indicated. Electroretinography can help diagnose retinal dystrophies.
Management depends entirely on the underlying cause. Retinoblastoma requires urgent oncologic management, including chemotherapy and sometimes enucleation. Infectious lesions may require antimicrobial therapy if active, while many congenital scars are inactive and require observation. Developmental anomalies like coloboma are monitored for complications such as retinal detachment, and patients with retinal dystrophies benefit from supportive care and low vision rehabilitation.
Prognosis varies widely. Some lesions, such as inactive scars, may have minimal visual impact, while others like retinoblastoma or Leber congenital amaurosis can lead to severe visual loss or even be life-threatening. Important complications include retinal detachment in coloboma, reactivation in toxoplasmosis, and systemic spread or secondary malignancies in retinoblastoma.
Congenital hypopigmented retinal lesions are a diverse group of conditions characterized by reduced or absent pigmentation of the retinal pigment epithelium (RPE) or choroid present at birth. These lesions are not a single disease entity but rather include a wide spectrum of pathologies such as tumors, congenital infections, retinal dystrophies, and developmental abnormalities. Clinically, they may appear as white or pale areas in the fundus and can vary in size, location, and associated findings.
A critical point in evaluation is that any white retinal lesion in infancy must prompt urgent consideration of Retinoblastoma, a life-threatening malignancy. Other important causes include infectious etiologies such as Toxoplasmosis, Cytomegalovirus infection, and Varicella, which typically produce chorioretinal scars. Developmental anomalies like Coloboma and inherited retinal dystrophies such as Leber congenital amaurosis are also included in the differential diagnosis.
The underlying pathophysiology depends on the cause. In some cases, there is a primary defect in melanin production within the RPE, while in others, such as infections, there is destruction of the RPE. Developmental conditions like coloboma result from failure of closure of the embryonic fissure, leading to absence of normal retinal and choroidal structures. Neoplastic processes, such as retinoblastoma or astrocytic hamartoma, involve abnormal cellular proliferation.
Patients may present with leukocoria, decreased vision, strabismus, or may be asymptomatic with incidental findings on examination. Associated systemic features are common, particularly in congenital infections and genetic syndromes. Diagnosis relies on a thorough ophthalmic examination supported by imaging such as ocular ultrasound (especially useful for detecting calcification in retinoblastoma), MRI or CT for intracranial or orbital involvement, and laboratory testing including TORCH screening and genetic analysis when indicated. Electroretinography can help diagnose retinal dystrophies.
Management depends entirely on the underlying cause. Retinoblastoma requires urgent oncologic management, including chemotherapy and sometimes enucleation. Infectious lesions may require antimicrobial therapy if active, while many congenital scars are inactive and require observation. Developmental anomalies like coloboma are monitored for complications such as retinal detachment, and patients with retinal dystrophies benefit from supportive care and low vision rehabilitation.
Prognosis varies widely. Some lesions, such as inactive scars, may have minimal visual impact, while others like retinoblastoma or Leber congenital amaurosis can lead to severe visual loss or even be life-threatening. Important complications include retinal detachment in coloboma, reactivation in toxoplasmosis, and systemic spread or secondary malignancies in retinoblastoma.
- Published on
Ophthalmology – Contact Lens Complications
Contact lens complications can occur in any wearer and range from mild irritation to severe, vision-threatening infections. These complications are broadly categorized into infectious (bacterial, fungal, Acanthamoeba), allergic (giant papillary conjunctivitis), hypoxic (overwear-related), toxic (solution-related), and structural changes such as corneal warpage. Although most issues are preventable, improper lens hygiene and overwear remain major contributors.
The most serious complication is infectious keratitis, particularly bacterial keratitis, which presents with pain, redness, photophobia, and decreased vision. On examination, there is typically a dense corneal infiltrate with an epithelial defect, surrounding edema, and sometimes hypopyon. Fungal keratitis appears more fluffy with satellite lesions, while Acanthamoeba keratitis—often linked to exposure to contaminated water (e.g., lakes, tap water)—causes severe pain out of proportion to findings and may show radial keratoneuritis or a ring infiltrate (late sign).
Noninfectious complications are also common. Contact lens overwear leads to corneal hypoxia, resulting in punctate keratitis, subepithelial infiltrates, and corneal neovascularization. Toxic keratitis can occur from improper use of multipurpose solutions or unneutralized hydrogen peroxide, presenting as diffuse epithelial damage. Giant papillary conjunctivitis (GPC) is an immune-mediated reaction characterized by large papillae on the upper tarsal conjunctiva, itching, and mucus discharge, often related to lens deposits or material.
Diagnosis relies on a careful history of contact lens use, hygiene practices, and symptom onset, along with slit-lamp examination. In suspected infections, corneal scrapings for culture and staining are essential to identify the causative organism and guide therapy.
Management depends on the underlying cause. Bacterial keratitis is treated urgently with frequent topical antibiotics (e.g., fluoroquinolones or fortified antibiotics). Fungal infections require antifungals such as natamycin, while Acanthamoeba keratitis is treated with agents like PHMB and propamidine. Noninfectious conditions improve with cessation of lens use, lubrication, and sometimes topical steroids or antihistamines (for GPC). Severe or nonresponsive infections may require corneal transplantation.
Prevention is critical and includes avoiding overnight wear, proper cleaning and storage, regular replacement of lenses and cases, and avoiding water exposure while wearing lenses. Daily disposable lenses significantly reduce risk.
The prognosis is generally good for mild complications, but central or severe infections can lead to permanent vision loss, especially if treatment is delayed or inappropriate (e.g., steroid use in active infection).
Contact lens complications can occur in any wearer and range from mild irritation to severe, vision-threatening infections. These complications are broadly categorized into infectious (bacterial, fungal, Acanthamoeba), allergic (giant papillary conjunctivitis), hypoxic (overwear-related), toxic (solution-related), and structural changes such as corneal warpage. Although most issues are preventable, improper lens hygiene and overwear remain major contributors.
The most serious complication is infectious keratitis, particularly bacterial keratitis, which presents with pain, redness, photophobia, and decreased vision. On examination, there is typically a dense corneal infiltrate with an epithelial defect, surrounding edema, and sometimes hypopyon. Fungal keratitis appears more fluffy with satellite lesions, while Acanthamoeba keratitis—often linked to exposure to contaminated water (e.g., lakes, tap water)—causes severe pain out of proportion to findings and may show radial keratoneuritis or a ring infiltrate (late sign).
Noninfectious complications are also common. Contact lens overwear leads to corneal hypoxia, resulting in punctate keratitis, subepithelial infiltrates, and corneal neovascularization. Toxic keratitis can occur from improper use of multipurpose solutions or unneutralized hydrogen peroxide, presenting as diffuse epithelial damage. Giant papillary conjunctivitis (GPC) is an immune-mediated reaction characterized by large papillae on the upper tarsal conjunctiva, itching, and mucus discharge, often related to lens deposits or material.
Diagnosis relies on a careful history of contact lens use, hygiene practices, and symptom onset, along with slit-lamp examination. In suspected infections, corneal scrapings for culture and staining are essential to identify the causative organism and guide therapy.
Management depends on the underlying cause. Bacterial keratitis is treated urgently with frequent topical antibiotics (e.g., fluoroquinolones or fortified antibiotics). Fungal infections require antifungals such as natamycin, while Acanthamoeba keratitis is treated with agents like PHMB and propamidine. Noninfectious conditions improve with cessation of lens use, lubrication, and sometimes topical steroids or antihistamines (for GPC). Severe or nonresponsive infections may require corneal transplantation.
Prevention is critical and includes avoiding overnight wear, proper cleaning and storage, regular replacement of lenses and cases, and avoiding water exposure while wearing lenses. Daily disposable lenses significantly reduce risk.
The prognosis is generally good for mild complications, but central or severe infections can lead to permanent vision loss, especially if treatment is delayed or inappropriate (e.g., steroid use in active infection).
- Published on
Ophthalmology – Contact Lens Complications
Contact lens complications can occur in any wearer and range from mild irritation to severe, vision-threatening infections. These complications are broadly categorized into infectious (bacterial, fungal, Acanthamoeba), allergic (giant papillary conjunctivitis), hypoxic (overwear-related), toxic (solution-related), and structural changes such as corneal warpage. Although most issues are preventable, improper lens hygiene and overwear remain major contributors.
The most serious complication is infectious keratitis, particularly bacterial keratitis, which presents with pain, redness, photophobia, and decreased vision. On examination, there is typically a dense corneal infiltrate with an epithelial defect, surrounding edema, and sometimes hypopyon. Fungal keratitis appears more fluffy with satellite lesions, while Acanthamoeba keratitis—often linked to exposure to contaminated water (e.g., lakes, tap water)—causes severe pain out of proportion to findings and may show radial keratoneuritis or a ring infiltrate (late sign).
Noninfectious complications are also common. Contact lens overwear leads to corneal hypoxia, resulting in punctate keratitis, subepithelial infiltrates, and corneal neovascularization. Toxic keratitis can occur from improper use of multipurpose solutions or unneutralized hydrogen peroxide, presenting as diffuse epithelial damage. Giant papillary conjunctivitis (GPC) is an immune-mediated reaction characterized by large papillae on the upper tarsal conjunctiva, itching, and mucus discharge, often related to lens deposits or material.
Diagnosis relies on a careful history of contact lens use, hygiene practices, and symptom onset, along with slit-lamp examination. In suspected infections, corneal scrapings for culture and staining are essential to identify the causative organism and guide therapy.
Management depends on the underlying cause. Bacterial keratitis is treated urgently with frequent topical antibiotics (e.g., fluoroquinolones or fortified antibiotics). Fungal infections require antifungals such as natamycin, while Acanthamoeba keratitis is treated with agents like PHMB and propamidine. Noninfectious conditions improve with cessation of lens use, lubrication, and sometimes topical steroids or antihistamines (for GPC). Severe or nonresponsive infections may require corneal transplantation.
Prevention is critical and includes avoiding overnight wear, proper cleaning and storage, regular replacement of lenses and cases, and avoiding water exposure while wearing lenses. Daily disposable lenses significantly reduce risk.
The prognosis is generally good for mild complications, but central or severe infections can lead to permanent vision loss, especially if treatment is delayed or inappropriate (e.g., steroid use in active infection).
Contact lens complications can occur in any wearer and range from mild irritation to severe, vision-threatening infections. These complications are broadly categorized into infectious (bacterial, fungal, Acanthamoeba), allergic (giant papillary conjunctivitis), hypoxic (overwear-related), toxic (solution-related), and structural changes such as corneal warpage. Although most issues are preventable, improper lens hygiene and overwear remain major contributors.
The most serious complication is infectious keratitis, particularly bacterial keratitis, which presents with pain, redness, photophobia, and decreased vision. On examination, there is typically a dense corneal infiltrate with an epithelial defect, surrounding edema, and sometimes hypopyon. Fungal keratitis appears more fluffy with satellite lesions, while Acanthamoeba keratitis—often linked to exposure to contaminated water (e.g., lakes, tap water)—causes severe pain out of proportion to findings and may show radial keratoneuritis or a ring infiltrate (late sign).
Noninfectious complications are also common. Contact lens overwear leads to corneal hypoxia, resulting in punctate keratitis, subepithelial infiltrates, and corneal neovascularization. Toxic keratitis can occur from improper use of multipurpose solutions or unneutralized hydrogen peroxide, presenting as diffuse epithelial damage. Giant papillary conjunctivitis (GPC) is an immune-mediated reaction characterized by large papillae on the upper tarsal conjunctiva, itching, and mucus discharge, often related to lens deposits or material.
Diagnosis relies on a careful history of contact lens use, hygiene practices, and symptom onset, along with slit-lamp examination. In suspected infections, corneal scrapings for culture and staining are essential to identify the causative organism and guide therapy.
Management depends on the underlying cause. Bacterial keratitis is treated urgently with frequent topical antibiotics (e.g., fluoroquinolones or fortified antibiotics). Fungal infections require antifungals such as natamycin, while Acanthamoeba keratitis is treated with agents like PHMB and propamidine. Noninfectious conditions improve with cessation of lens use, lubrication, and sometimes topical steroids or antihistamines (for GPC). Severe or nonresponsive infections may require corneal transplantation.
Prevention is critical and includes avoiding overnight wear, proper cleaning and storage, regular replacement of lenses and cases, and avoiding water exposure while wearing lenses. Daily disposable lenses significantly reduce risk.
The prognosis is generally good for mild complications, but central or severe infections can lead to permanent vision loss, especially if treatment is delayed or inappropriate (e.g., steroid use in active infection).
- Published on
Ophthalmology – Acute Viral Conjunctivitis
Acute viral conjunctivitis is a very common inflammation of the conjunctiva, most frequently caused by adenovirus, which accounts for the majority of cases worldwide. It affects individuals of all ages and is highly contagious, often spreading rapidly in households, schools, and crowded environments. Viral conjunctivitis represents 20–70% of all acute conjunctivitis cases, making it the most common overall cause.
Patients typically present with a red eye that begins in one eye and spreads to the other within a few days, accompanied by watery or mucoid discharge, irritation, and tearing. A history of recent upper respiratory infection or contact with an infected person is common. Compared to bacterial conjunctivitis, the discharge is more watery rather than purulent. Many patients also develop preauricular lymphadenopathy, which is a helpful distinguishing feature.
On examination, findings include conjunctival injection, follicular reaction on the palpebral conjunctiva, and sometimes microhemorrhages. In more severe forms such as epidemic keratoconjunctivitis (EKC), patients may develop pseudomembranes and later subepithelial infiltrates in the cornea, which can cause decreased vision and photophobia. These infiltrates typically appear 7–10 days after onset. Other viral forms include pharyngoconjunctival fever (PCF) and acute hemorrhagic conjunctivitis.
Diagnosis is primarily clinical, although rapid point-of-care adenovirus testing is available and can confirm the diagnosis within minutes. More advanced tests such as PCR or viral culture are rarely needed in routine cases. It is important to distinguish viral conjunctivitis from bacterial, allergic, or more serious ocular conditions.
Treatment is mainly supportive, as there are no FDA-approved antiviral agents for adenoviral conjunctivitis. Recommended measures include frequent use of preservative-free artificial tears, cold compresses, and strict hygiene practices such as handwashing and avoiding shared towels. Topical antihistamines may help with itching. In cases caused by herpes simplex virus (HSV), antiviral therapy such as topical ganciclovir or trifluridine is required.
Topical steroids may be used cautiously in severe cases with pseudomembranes or visually significant subepithelial infiltrates, but they should be avoided in mild disease because they can prolong viral shedding and worsen infection.
The prognosis is generally excellent, with most patients recovering spontaneously within 1–2 weeks. However, some patients—especially those with EKC—may develop persistent subepithelial infiltrates or chronic dry eye symptoms, which can last for weeks to months. Patients should be educated about the highly contagious nature of the disease and advised that antibiotics are ineffective unless a secondary bacterial infection is present.
Acute viral conjunctivitis is a very common inflammation of the conjunctiva, most frequently caused by adenovirus, which accounts for the majority of cases worldwide. It affects individuals of all ages and is highly contagious, often spreading rapidly in households, schools, and crowded environments. Viral conjunctivitis represents 20–70% of all acute conjunctivitis cases, making it the most common overall cause.
Patients typically present with a red eye that begins in one eye and spreads to the other within a few days, accompanied by watery or mucoid discharge, irritation, and tearing. A history of recent upper respiratory infection or contact with an infected person is common. Compared to bacterial conjunctivitis, the discharge is more watery rather than purulent. Many patients also develop preauricular lymphadenopathy, which is a helpful distinguishing feature.
On examination, findings include conjunctival injection, follicular reaction on the palpebral conjunctiva, and sometimes microhemorrhages. In more severe forms such as epidemic keratoconjunctivitis (EKC), patients may develop pseudomembranes and later subepithelial infiltrates in the cornea, which can cause decreased vision and photophobia. These infiltrates typically appear 7–10 days after onset. Other viral forms include pharyngoconjunctival fever (PCF) and acute hemorrhagic conjunctivitis.
Diagnosis is primarily clinical, although rapid point-of-care adenovirus testing is available and can confirm the diagnosis within minutes. More advanced tests such as PCR or viral culture are rarely needed in routine cases. It is important to distinguish viral conjunctivitis from bacterial, allergic, or more serious ocular conditions.
Treatment is mainly supportive, as there are no FDA-approved antiviral agents for adenoviral conjunctivitis. Recommended measures include frequent use of preservative-free artificial tears, cold compresses, and strict hygiene practices such as handwashing and avoiding shared towels. Topical antihistamines may help with itching. In cases caused by herpes simplex virus (HSV), antiviral therapy such as topical ganciclovir or trifluridine is required.
Topical steroids may be used cautiously in severe cases with pseudomembranes or visually significant subepithelial infiltrates, but they should be avoided in mild disease because they can prolong viral shedding and worsen infection.
The prognosis is generally excellent, with most patients recovering spontaneously within 1–2 weeks. However, some patients—especially those with EKC—may develop persistent subepithelial infiltrates or chronic dry eye symptoms, which can last for weeks to months. Patients should be educated about the highly contagious nature of the disease and advised that antibiotics are ineffective unless a secondary bacterial infection is present.
- Published on
Ophthalmology – Acute Bacterial Conjunctivitis
Acute bacterial conjunctivitis is a common inflammation of the conjunctiva, the mucous membrane lining the inner eyelids and covering the sclera. It affects individuals of all ages and is particularly frequent in children, where bacteria account for the majority of infectious conjunctivitis cases. The condition is highly contagious and represents a significant portion of primary care and ophthalmology visits.
Patients typically present with a red eye accompanied by purulent (yellow-green) discharge, which often leads to eyelid crusting or “glued eyes” upon waking. Symptoms frequently involve both eyes, though one eye may be affected first. Other features include irritation, tearing, and mild discomfort. Unlike viral conjunctivitis, watery discharge is less prominent, and severe pain or vision loss should prompt evaluation for alternative diagnoses. In hyperacute cases—most notably caused by Neisseria gonorrhoeae—patients may develop copious discharge and rapid progression, posing a risk for corneal damage.
The most common causative organisms include Staphylococcus aureus (more common in adults), Haemophilus influenzae and Streptococcus pneumoniae (common in children), and Moraxella catarrhalis. Chronic cases may be caused by Chlamydia, while hyperacute cases are associated with gonococcal infection. Risk factors include close contact with infected individuals, sinusitis, and immunocompromised states.
Diagnosis is usually clinical, though it can be challenging to distinguish from viral conjunctivitis based on symptoms alone. On examination, findings may include conjunctival injection, papillary reaction, and purulent discharge. Preauricular lymphadenopathy is uncommon in bacterial cases. Laboratory testing (culture or Gram stain) is reserved for severe, recurrent, or nonresponsive cases, or when gonococcal or chlamydial infection is suspected.
Treatment typically involves topical antibiotics, which shorten the duration of symptoms and reduce transmission. First-line options include trimethoprim-polymyxin B or fluoroquinolone eye drops for about 7 days. Hyperacute gonococcal conjunctivitis requires systemic antibiotics such as intramuscular ceftriaxone, often combined with topical therapy and close follow-up due to the risk of corneal ulceration and perforation. Supportive care includes artificial tears, good hygiene, and avoidance of sharing personal items.
The prognosis is excellent, as most cases are self-limiting, even without treatment. However, antibiotics speed recovery and reduce spread. Patients should be advised that they remain contagious for 24–48 hours after starting antibiotics. Follow-up is recommended if symptoms worsen, vision decreases, or there is no improvement within a week. Complications are rare but may include keratitis in severe or untreated cases.
Acute bacterial conjunctivitis is a common inflammation of the conjunctiva, the mucous membrane lining the inner eyelids and covering the sclera. It affects individuals of all ages and is particularly frequent in children, where bacteria account for the majority of infectious conjunctivitis cases. The condition is highly contagious and represents a significant portion of primary care and ophthalmology visits.
Patients typically present with a red eye accompanied by purulent (yellow-green) discharge, which often leads to eyelid crusting or “glued eyes” upon waking. Symptoms frequently involve both eyes, though one eye may be affected first. Other features include irritation, tearing, and mild discomfort. Unlike viral conjunctivitis, watery discharge is less prominent, and severe pain or vision loss should prompt evaluation for alternative diagnoses. In hyperacute cases—most notably caused by Neisseria gonorrhoeae—patients may develop copious discharge and rapid progression, posing a risk for corneal damage.
The most common causative organisms include Staphylococcus aureus (more common in adults), Haemophilus influenzae and Streptococcus pneumoniae (common in children), and Moraxella catarrhalis. Chronic cases may be caused by Chlamydia, while hyperacute cases are associated with gonococcal infection. Risk factors include close contact with infected individuals, sinusitis, and immunocompromised states.
Diagnosis is usually clinical, though it can be challenging to distinguish from viral conjunctivitis based on symptoms alone. On examination, findings may include conjunctival injection, papillary reaction, and purulent discharge. Preauricular lymphadenopathy is uncommon in bacterial cases. Laboratory testing (culture or Gram stain) is reserved for severe, recurrent, or nonresponsive cases, or when gonococcal or chlamydial infection is suspected.
Treatment typically involves topical antibiotics, which shorten the duration of symptoms and reduce transmission. First-line options include trimethoprim-polymyxin B or fluoroquinolone eye drops for about 7 days. Hyperacute gonococcal conjunctivitis requires systemic antibiotics such as intramuscular ceftriaxone, often combined with topical therapy and close follow-up due to the risk of corneal ulceration and perforation. Supportive care includes artificial tears, good hygiene, and avoidance of sharing personal items.
The prognosis is excellent, as most cases are self-limiting, even without treatment. However, antibiotics speed recovery and reduce spread. Patients should be advised that they remain contagious for 24–48 hours after starting antibiotics. Follow-up is recommended if symptoms worsen, vision decreases, or there is no improvement within a week. Complications are rare but may include keratitis in severe or untreated cases.
- Published on
Ophthalmology – Conjunctival Primary Acquired Melanosis (PAM)
Conjunctival primary acquired melanosis (PAM) is an acquired, flat pigmentation of the conjunctiva that typically develops in middle-aged or older adults, most often in individuals with lighter skin. It is usually unilateral, nonhereditary, and slowly progressive, and can involve multiple regions of the conjunctiva including the limbus, bulbar surface, fornix, caruncle, and even the tarsal conjunctiva. Unlike conjunctival melanoma, PAM generally lacks prominent vascularity and appears as a patchy, brown discoloration of the ocular surface.
The clinical importance of PAM lies in its potential to act as a precursor to conjunctival melanoma, particularly when atypia is present. Patients often report a gradually enlarging pigmented area on the eye, although many remain asymptomatic. The condition is more common in Caucasians and has been associated with sunlight exposure, though no single definitive risk factor has been identified.
Pathophysiologically, PAM begins as melanocytic proliferation in the basal layer of the conjunctival epithelium. In cases with atypia, these abnormal melanocytes can extend upward through the epithelial layers and eventually penetrate the basement membrane, transforming into invasive melanoma. Histologically, PAM is classified into two main types: without atypia (benign) and with atypia (premalignant). The risk of progression to melanoma is negligible in PAM without atypia but increases significantly with atypia—especially severe atypia, where transformation risk can be very high.
Diagnosis is primarily clinical, supported by careful slit-lamp examination and documentation of lesion extent (often measured in clock hours). Imaging such as anterior segment OCT may help confirm that the lesion is superficial without deeper invasion. In selected cases, biopsy or cytologic evaluation may be performed to assess for atypia, although some clinicians prefer to proceed directly to treatment without prior manipulation.
Management depends on the extent and histologic features of the lesion. Small areas may be observed, especially if atypia is not suspected. More extensive or suspicious lesions are typically treated with surgical excision combined with cryotherapy to surrounding tissue. For diffuse or recurrent disease, topical chemotherapy agents such as mitomycin C may be used, and in extensive cases, even radiotherapy can be considered. The goal is to eliminate abnormal pigmentation and reduce the risk of malignant transformation.
Lifelong follow-up is essential. Patients are usually monitored every 3–4 months initially, then every 6 months once stability is established. Regular examinations focus on detecting growth, recurrence, or transformation into melanoma.
The prognosis is excellent if PAM remains non-atypical. However, once transformation to melanoma occurs, the prognosis becomes more guarded due to the risk of metastasis. Complications from treatment may include ocular surface issues such as dry eye, scarring, symblepharon, and, rarely, vision loss, particularly in advanced or extensively treated cases.
Conjunctival primary acquired melanosis (PAM) is an acquired, flat pigmentation of the conjunctiva that typically develops in middle-aged or older adults, most often in individuals with lighter skin. It is usually unilateral, nonhereditary, and slowly progressive, and can involve multiple regions of the conjunctiva including the limbus, bulbar surface, fornix, caruncle, and even the tarsal conjunctiva. Unlike conjunctival melanoma, PAM generally lacks prominent vascularity and appears as a patchy, brown discoloration of the ocular surface.
The clinical importance of PAM lies in its potential to act as a precursor to conjunctival melanoma, particularly when atypia is present. Patients often report a gradually enlarging pigmented area on the eye, although many remain asymptomatic. The condition is more common in Caucasians and has been associated with sunlight exposure, though no single definitive risk factor has been identified.
Pathophysiologically, PAM begins as melanocytic proliferation in the basal layer of the conjunctival epithelium. In cases with atypia, these abnormal melanocytes can extend upward through the epithelial layers and eventually penetrate the basement membrane, transforming into invasive melanoma. Histologically, PAM is classified into two main types: without atypia (benign) and with atypia (premalignant). The risk of progression to melanoma is negligible in PAM without atypia but increases significantly with atypia—especially severe atypia, where transformation risk can be very high.
Diagnosis is primarily clinical, supported by careful slit-lamp examination and documentation of lesion extent (often measured in clock hours). Imaging such as anterior segment OCT may help confirm that the lesion is superficial without deeper invasion. In selected cases, biopsy or cytologic evaluation may be performed to assess for atypia, although some clinicians prefer to proceed directly to treatment without prior manipulation.
Management depends on the extent and histologic features of the lesion. Small areas may be observed, especially if atypia is not suspected. More extensive or suspicious lesions are typically treated with surgical excision combined with cryotherapy to surrounding tissue. For diffuse or recurrent disease, topical chemotherapy agents such as mitomycin C may be used, and in extensive cases, even radiotherapy can be considered. The goal is to eliminate abnormal pigmentation and reduce the risk of malignant transformation.
Lifelong follow-up is essential. Patients are usually monitored every 3–4 months initially, then every 6 months once stability is established. Regular examinations focus on detecting growth, recurrence, or transformation into melanoma.
The prognosis is excellent if PAM remains non-atypical. However, once transformation to melanoma occurs, the prognosis becomes more guarded due to the risk of metastasis. Complications from treatment may include ocular surface issues such as dry eye, scarring, symblepharon, and, rarely, vision loss, particularly in advanced or extensively treated cases.
- Published on
Ophthalmology – Conjunctival Nevus
Conjunctival nevus is the most common conjunctival tumor, accounting for a large proportion of melanocytic lesions of the ocular surface. It is typically a benign proliferation of melanocytes and may be present at birth (congenital) or develop during childhood or adolescence. Most lesions become clinically noticeable in the first or second decade of life and can change in pigmentation over time, particularly during periods of hormonal change such as puberty.
Clinically, conjunctival nevi appear as well-defined, slightly elevated lesions that may be pigmented (brown) or amelanotic (nonpigmented). A key distinguishing feature is the presence of intralesional cysts, which are often visible on slit-lamp examination and help differentiate nevi from malignant lesions. These lesions are most commonly located on the bulbar conjunctiva, especially near the nasal or temporal limbus in sun-exposed areas. Importantly, they usually do not extend onto the cornea and tend to move with the conjunctiva.
Most patients are asymptomatic and simply notice a “spot on the eye.” Occasionally, mild irritation or inflammation may occur. The condition is generally sporadic and rarely associated with systemic disease, although uncommon associations with syndromes like Carney complex have been reported.
Diagnosis is primarily clinical, supported by slit-lamp examination and photographic documentation. Anterior segment OCT can help identify cystic components within the lesion. Regular follow-up with serial photography every 6–12 months is recommended to monitor for changes in size, shape, or pigmentation.
Management is usually conservative. Observation is the standard approach for typical, stable lesions. However, surgical excision may be indicated if there are suspicious features such as documented growth, absence of cysts, prominent feeder vessels, unusual location (e.g., forniceal or tarsal conjunctiva), corneal involvement, or onset later in life. Excision is performed using a “no-touch” technique with cryotherapy to margins to reduce the risk of recurrence or malignant transformation.
The prognosis is excellent in the vast majority of cases, as conjunctival nevi are benign. Malignant transformation into melanoma is rare but possible, which is why periodic monitoring is essential. Complications are uncommon but may include mild irritation or dry eye following surgical removal.
Conjunctival nevus is the most common conjunctival tumor, accounting for a large proportion of melanocytic lesions of the ocular surface. It is typically a benign proliferation of melanocytes and may be present at birth (congenital) or develop during childhood or adolescence. Most lesions become clinically noticeable in the first or second decade of life and can change in pigmentation over time, particularly during periods of hormonal change such as puberty.
Clinically, conjunctival nevi appear as well-defined, slightly elevated lesions that may be pigmented (brown) or amelanotic (nonpigmented). A key distinguishing feature is the presence of intralesional cysts, which are often visible on slit-lamp examination and help differentiate nevi from malignant lesions. These lesions are most commonly located on the bulbar conjunctiva, especially near the nasal or temporal limbus in sun-exposed areas. Importantly, they usually do not extend onto the cornea and tend to move with the conjunctiva.
Most patients are asymptomatic and simply notice a “spot on the eye.” Occasionally, mild irritation or inflammation may occur. The condition is generally sporadic and rarely associated with systemic disease, although uncommon associations with syndromes like Carney complex have been reported.
Diagnosis is primarily clinical, supported by slit-lamp examination and photographic documentation. Anterior segment OCT can help identify cystic components within the lesion. Regular follow-up with serial photography every 6–12 months is recommended to monitor for changes in size, shape, or pigmentation.
Management is usually conservative. Observation is the standard approach for typical, stable lesions. However, surgical excision may be indicated if there are suspicious features such as documented growth, absence of cysts, prominent feeder vessels, unusual location (e.g., forniceal or tarsal conjunctiva), corneal involvement, or onset later in life. Excision is performed using a “no-touch” technique with cryotherapy to margins to reduce the risk of recurrence or malignant transformation.
The prognosis is excellent in the vast majority of cases, as conjunctival nevi are benign. Malignant transformation into melanoma is rare but possible, which is why periodic monitoring is essential. Complications are uncommon but may include mild irritation or dry eye following surgical removal.
- Published on
Ophthalmology – Conjunctival Melanoma
Conjunctival melanoma is a malignant tumor of the conjunctiva, the mucous membrane covering the white of the eye and inner eyelids. It is typically pigmented (brown or black) but can also be nonpigmented (pink), which can make diagnosis more challenging. This tumor usually develops slowly over months to years and most commonly affects middle-aged to older adults, particularly those of Caucasian background. Although often painless, it can appear as a red, irritated eye due to associated vascularity.
A key feature is its association with primary acquired melanosis (PAM), a flat conjunctival pigmentation that can transform into melanoma over time—especially when atypia is present. Less commonly, conjunctival melanoma may arise from a pre-existing nevus. Clinically, the lesion appears as a nodular or elevated mass with prominent feeder blood vessels, sometimes surrounded by a “wreath” of dilated vessels. It can occur anywhere on the conjunctiva, including the limbus, bulbar surface, fornix, or caruncle, and may be unifocal or multifocal.
Despite its often slow growth, conjunctival melanoma is a serious condition with metastatic potential. It can invade locally into the eye or orbit and spread to regional lymph nodes, lungs, or brain. The overall risk of metastasis is approximately 25%, and mortality is a significant concern. Tumor size and location influence prognosis, with larger and more posterior lesions carrying higher risk.
Diagnosis is primarily clinical, supported by slit-lamp examination and detailed photographic documentation. It is critical to examine all conjunctival surfaces, including under the eyelids, and to assess for associated PAM. Imaging such as anterior segment OCT or MRI may be used if deeper invasion is suspected. Unlike many tumors, incisional biopsy is avoided due to the risk of tumor seeding; instead, management proceeds directly to excision.
The cornerstone of treatment is complete surgical excision using a “no-touch” technique, which minimizes manipulation of the tumor to prevent dissemination. This is combined with cryotherapy to surrounding tissue and treatment of any associated PAM. Additional therapies may include topical chemotherapy agents such as mitomycin C, 5-fluorouracil, or interferon for residual disease. In advanced cases with deeper invasion, radiotherapy or even orbital exenteration may be required.
Close, lifelong follow-up is essential due to the high risk of recurrence and metastasis. Patients are typically monitored every few months initially, then less frequently if stable. Systemic evaluation for metastatic disease—especially involving lymph nodes, lungs, and brain—is a critical component of care.
Prognosis varies. Recurrence rates are relatively high, and metastasis increases over time. However, many patients retain useful vision, especially with early detection and proper treatment. Complications can include vision loss, scarring, dry eye, diplopia, and, in severe cases, need for extensive surgical intervention.
Conjunctival melanoma is a malignant tumor of the conjunctiva, the mucous membrane covering the white of the eye and inner eyelids. It is typically pigmented (brown or black) but can also be nonpigmented (pink), which can make diagnosis more challenging. This tumor usually develops slowly over months to years and most commonly affects middle-aged to older adults, particularly those of Caucasian background. Although often painless, it can appear as a red, irritated eye due to associated vascularity.
A key feature is its association with primary acquired melanosis (PAM), a flat conjunctival pigmentation that can transform into melanoma over time—especially when atypia is present. Less commonly, conjunctival melanoma may arise from a pre-existing nevus. Clinically, the lesion appears as a nodular or elevated mass with prominent feeder blood vessels, sometimes surrounded by a “wreath” of dilated vessels. It can occur anywhere on the conjunctiva, including the limbus, bulbar surface, fornix, or caruncle, and may be unifocal or multifocal.
Despite its often slow growth, conjunctival melanoma is a serious condition with metastatic potential. It can invade locally into the eye or orbit and spread to regional lymph nodes, lungs, or brain. The overall risk of metastasis is approximately 25%, and mortality is a significant concern. Tumor size and location influence prognosis, with larger and more posterior lesions carrying higher risk.
Diagnosis is primarily clinical, supported by slit-lamp examination and detailed photographic documentation. It is critical to examine all conjunctival surfaces, including under the eyelids, and to assess for associated PAM. Imaging such as anterior segment OCT or MRI may be used if deeper invasion is suspected. Unlike many tumors, incisional biopsy is avoided due to the risk of tumor seeding; instead, management proceeds directly to excision.
The cornerstone of treatment is complete surgical excision using a “no-touch” technique, which minimizes manipulation of the tumor to prevent dissemination. This is combined with cryotherapy to surrounding tissue and treatment of any associated PAM. Additional therapies may include topical chemotherapy agents such as mitomycin C, 5-fluorouracil, or interferon for residual disease. In advanced cases with deeper invasion, radiotherapy or even orbital exenteration may be required.
Close, lifelong follow-up is essential due to the high risk of recurrence and metastasis. Patients are typically monitored every few months initially, then less frequently if stable. Systemic evaluation for metastatic disease—especially involving lymph nodes, lungs, and brain—is a critical component of care.
Prognosis varies. Recurrence rates are relatively high, and metastasis increases over time. However, many patients retain useful vision, especially with early detection and proper treatment. Complications can include vision loss, scarring, dry eye, diplopia, and, in severe cases, need for extensive surgical intervention.
- Published on
Ophthalmology – Conjunctival and Corneal Lacerations
Conjunctival and corneal lacerations are tears or cuts of the ocular surface caused by blunt or penetrating trauma. These injuries range from superficial partial-thickness defects to full-thickness open globe injuries, which are vision-threatening emergencies. They are more common in young males and are frequently associated with occupational or recreational activities where protective eyewear is not used.
Patients typically present with pain, redness, tearing, photophobia, and foreign body sensation. A careful history is critical, especially regarding the mechanism of injury, as high-velocity trauma (e.g., metal-on-metal or BB gun injuries) raises strong concern for intraocular foreign body (IOFB) or globe rupture. Determining the timing of last oral intake is also important if urgent surgery is required.
On examination, minimal manipulation of the eye is essential to avoid worsening a possible open globe injury. Visual acuity should always be checked, but intraocular pressure must not be measured if a full-thickness laceration is suspected. Slit-lamp examination helps assess the size, depth, and location of the wound. Fluorescein staining can highlight epithelial defects, and a positive Seidel test confirms aqueous leakage, indicating a full-thickness laceration. Additional concerning signs include irregular pupil, shallow or deep anterior chamber, hyphema, hypotony, or vitreous hemorrhage. Both eyes must be examined carefully, and eyelid eversion should be performed when safe.
If an intraocular foreign body is suspected, orbital CT scan (thin cuts) is the imaging modality of choice, while MRI should be avoided if metallic material is possible. Even with normal imaging, persistent suspicion of globe injury may require surgical exploration.
Management depends on the severity of the injury. Small conjunctival lacerations without scleral involvement often heal with topical antibiotic ointment alone, while larger ones may require suturing. Partial-thickness corneal lacerations are treated with topical antibiotics and close observation, though some may need suturing if wound edges gape. In contrast, full-thickness corneal lacerations are ophthalmic emergencies requiring urgent surgical repair in the operating room. Patients should be protected with a rigid eye shield, kept NPO, and given systemic antibiotics to reduce infection risk. Antiemetics and pain control are important to prevent increases in intraocular pressure.
Surgical repair focuses on restoring globe integrity, carefully repositioning tissues, removing vitreous traction if present, and achieving watertight closure using fine sutures. Associated injuries such as traumatic cataract or iris damage are usually addressed later. Patients must be counseled about the rare but serious risk of sympathetic ophthalmia, which can affect the uninjured eye.
Close follow-up is required to monitor for complications such as infection, retinal detachment, or wound leakage. Children are at particular risk of amblyopia, requiring prompt visual rehabilitation. Prognosis varies widely depending on the severity of injury, timing of treatment, and presence of complications, with worse outcomes associated with delayed care or severe trauma.
Conjunctival and corneal lacerations are tears or cuts of the ocular surface caused by blunt or penetrating trauma. These injuries range from superficial partial-thickness defects to full-thickness open globe injuries, which are vision-threatening emergencies. They are more common in young males and are frequently associated with occupational or recreational activities where protective eyewear is not used.
Patients typically present with pain, redness, tearing, photophobia, and foreign body sensation. A careful history is critical, especially regarding the mechanism of injury, as high-velocity trauma (e.g., metal-on-metal or BB gun injuries) raises strong concern for intraocular foreign body (IOFB) or globe rupture. Determining the timing of last oral intake is also important if urgent surgery is required.
On examination, minimal manipulation of the eye is essential to avoid worsening a possible open globe injury. Visual acuity should always be checked, but intraocular pressure must not be measured if a full-thickness laceration is suspected. Slit-lamp examination helps assess the size, depth, and location of the wound. Fluorescein staining can highlight epithelial defects, and a positive Seidel test confirms aqueous leakage, indicating a full-thickness laceration. Additional concerning signs include irregular pupil, shallow or deep anterior chamber, hyphema, hypotony, or vitreous hemorrhage. Both eyes must be examined carefully, and eyelid eversion should be performed when safe.
If an intraocular foreign body is suspected, orbital CT scan (thin cuts) is the imaging modality of choice, while MRI should be avoided if metallic material is possible. Even with normal imaging, persistent suspicion of globe injury may require surgical exploration.
Management depends on the severity of the injury. Small conjunctival lacerations without scleral involvement often heal with topical antibiotic ointment alone, while larger ones may require suturing. Partial-thickness corneal lacerations are treated with topical antibiotics and close observation, though some may need suturing if wound edges gape. In contrast, full-thickness corneal lacerations are ophthalmic emergencies requiring urgent surgical repair in the operating room. Patients should be protected with a rigid eye shield, kept NPO, and given systemic antibiotics to reduce infection risk. Antiemetics and pain control are important to prevent increases in intraocular pressure.
Surgical repair focuses on restoring globe integrity, carefully repositioning tissues, removing vitreous traction if present, and achieving watertight closure using fine sutures. Associated injuries such as traumatic cataract or iris damage are usually addressed later. Patients must be counseled about the rare but serious risk of sympathetic ophthalmia, which can affect the uninjured eye.
Close follow-up is required to monitor for complications such as infection, retinal detachment, or wound leakage. Children are at particular risk of amblyopia, requiring prompt visual rehabilitation. Prognosis varies widely depending on the severity of injury, timing of treatment, and presence of complications, with worse outcomes associated with delayed care or severe trauma.
